Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response

To cite this version:
Olivier Cerles, Evelyne Benoit, Christiane Chéreau, Sandrine Chouzenoux, Florence Morin, et al.. Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response. Molecular Cancer Therapeutics, American Association for Cancer Research, 2017, 16 (2), pp.300-311. 10.1158/1535-7163.MCT-16-0326. cea-02121953

HAL Id: cea-02121953
https://hal-cea.archives-ouvertes.fr/cea-02121953
Submitted on 20 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
**Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response**

Olivier Cerles, Evelyne Benoit, Christiane Chéreau, Sandrine Chouzenoux, Florence Morin, Marie-Anne Guillamot, Romain Coriat, Niloufar Kavian, Thomas Loussier, Pietro Santulli, Louis Marcellin, Nathaniel E.B. Saidu, Bernard Weill, Frédéric Batteux, and Carole Nicco

**Abstract**

Neuropathic pain is a limiting factor of platinum-based chemotherapies. We sought to investigate the neuroprotective potential of niclosamide in peripheral neuropathies induced by oxaliplatin. Normal neuron-like and cancer cells were treated in vitro with oxaliplatin associated or not with an inhibitor of STAT3 and NF-kB, niclosamide. Cell production of reactive oxygen species and viability were measured by 2',7'-dichlorodihydrofluorescein diacetate and crystal violet. Peripheral neuropathies were induced in mice by oxaliplatin with or without niclosamide. Neurologic functions were assessed by behavioral and electrophysiologic tests, intraepidermal innervation, and myelination by immunohistochemical, histologic, and morphologic studies using confocal microscopy. Efficacy on tumor growth was assessed in mice grafted with CT26 colon cancer cells. In neuron-like cells, niclosamide downregulated the production of oxaliplatin-mediated H2O2, thereby preventing cell death. In colon cancer cells, niclosamide enhanced oxaliplatin-mediated cell death through increased H2O2 production. These observations were explained by inherent lower basal levels of GSH in cancer cells compared with normal and neuron-like cells. In neuropathic mice, niclosamide prevented tactile hyperesthesia and thermal hyperalgesia and abrogated membrane hyperexcitability. The tenascin-c also prevented intraepidermal nerve fiber density reduction and demyelination in oxaliplatin mice in this mixed form of peripheral neuropathy. Niclosamide prevents oxaliplatin-induced increased levels of IL6, TNFα, and advanced oxidized protein products. Niclosamide displayed antitumor effects while not abrogating oxaliplatin efficacy. These results indicate that niclosamide exerts its neuroprotection both in vitro and in vivo by limiting oxaliplatin-induced oxidative stress and neuroinflammation. These findings identify niclosamide as a promising therapeutic adjunct to oxaliplatin chemotherapy. *Mol Cancer Ther;* 16(2); 300–11. ©2016 AACR.

**Introduction**

Platinum-based chemotherapies elicit their antitumor effects by compromising the integrity of DNA via the formation of adducts and impairing the functioning of mitochondrial processes (1–3). These impairments ultimately lead to a burst of oxidative stress, which in turn promotes cell death processes (4). Oxaliplatin is able to induce functional abnormalities in dorsal root ganglia and axonal voltage-gated sodium channels as well as voltage-gated potassium channels (5–7). Oxaliplatin also induces a deregulation in calcium intracellular signaling as well as homeostasis (8, 9). This platinum-based chemotherapy indicated in metastatic colon cancers and colorectal cancers has also been shown to induce a rise in tumor cell production of reactive oxygen species (ROS; ref. 10). Oxaliplatin is indicated as a first-line and an adjuvant treatment. This molecule is associated with several toxicities, such as a high risk for allergic reactions, hepatotoxicity, and peripheral neuropathies that affect up to 95% of patients (11). Oxidative stress is a key factor in the induction of oxaliplatin-associated peripheral neuropathies (1, 12, 13). This oxidative stress has also been linked to transient receptor potential cation channel TRPA1, which acts as a sensor of electrophilic and reactive species generated during tissue injury and inflammation (14). It is thought that by-products generated by ROS following oxaliplatin treatment could activate TRPA1, thereby producing a nociceptive response and neurogenic inflammation (15). Furthermore, antioxidant molecules, such as vitamin C, acetyl-L-carnitine, and α-linoleic acid, can inhibit ROS-induced hyperalgesia in rats presenting peripheral neuropathies induced by oxaliplatin, via Ib4-positive nociceptors (16). This observation concurs with the fact that oxaliplatin can modulate sodium channel activity, thereby influencing the sensitivity of nociceptors (17). Oxaliplatin neurotoxicity may manifest within hours after injection as an acute reaction or as a chronic response.
resulting from cumulated high-dosage injections. The acute form, which is reversible and usually resolves within days following injection, is characterized by transient paresthesia and myotonia, whereas the chronic form presents persistent paresthesia and thermoalgesia (18). This toxicity may require lowering of doses and, in worst cases, interruption of the treatment (19). Targeting the pathogenic events leading to the oxidative burst witnessed upon injection of oxaliplatin may prove useful in preventing neurotoxicity.

Niclosamide is an anthelmintic drug with a well-known safety profile. This drug is known for its inhibitory effects on oxidative phosphorylating activity and for its anti-inflammatory properties. Niclosamide also exhibits antitumor effects through the inhibition of pathways commonly associated with oncogenesis, such as STAT3, NF-κB, Wnt/β-catenin, mTORC1, and Notch (20). Niclosamide sensitizes cancer cells that are nonresponsive to radiotherapy (21), and in vitro potentiation of the antitumor effects of chemotherapeutics upon association with niclosamide has been reported (22).

The anti-inflammatory properties of niclosamide prompted us to investigate in vitro and in vivo its protective potential in both preventing the neurologic impairments brought about by oxaliplatin, as well as enhancing its antitumor effect.

Materials and Methods

Cell culture and treatments
All cell lines were authenticated by short tandem repeat analysis and tested negative for mycoplasma in April 2014. CT26 (mouse colon carcinoma) cells, purchased from the ATCC in 2012, were grown in DMEM with 10% FBS, penicillin/glutamine, and 1-glutamine supplementation. N2a (mouse brain neuroblastoma) cells, purchased from the ATCC in 2012, were grown in Eagle Minimum Essential Medium supplemented with 10% FBS, penicillin/streptomycin, 2% sodium pyruvate, 1% ciprofloxacin, nonessential amino acids, and 1-glutamine supplementation. HUVECs (human umbilical vein endothelium), purchased from the ATCC in 2012, were grown in endothelial cell basal medium-2 with 10% FBS, 1% oxalic acid, nonessential amino acids, and 1-glutamine supplementation. CT26 (mouse brain neuroblastoma) cells, purchased from the ATCC in 2012, were grown in DMEM with 10% FBS, penicillin/streptomycin, and 1-glutamine supplementation. HUVECs (human umbilical vein endothelium), purchased from the ATCC in 2012, were grown in endothelial cell basal medium-2 with 10% FBS, 1% ciprofloxacin, penicillin/streptomycin, and essential amino acids. THP1 (human acute leukemia monocye) cells, purchased from the ATCC in 2012, were grown in RPMI medium 1640 with 10% FBS and penicillin/streptomycin.

ROS, GSH, and viability assays
All cells (1.5 × 10^5–10^6 per well) were seeded in 96-well plates (Corning) and incubated for 16 hours with 0.05 μmol/L of niclosamide (Sigma-Aldrich) and treated with 0 to 50 μmol/L of oxaliplatin (Accord Healthcare Limited). Cell viability was assessed by crystal violet assay, and results are expressed as the mean percentage of viable cells ± SD versus cells not exposed to oxaliplatin (100% viability). Cellular production of hydrogen peroxide (H_2O_2) and reduced glutathione (GSH) was assessed by spectrophotometry with 2',7'-dichlorodihydrofluorescein diacetate and monochlorobimane, respectively (10).

Drug treatment study
BALB/cJrJ male mice between 6 and 8 weeks of age were purchased (Janvier Labs). If not explicitly stated otherwise, mice received intraperitoneal injections (200 μL) of first, either oxaliplatin (10 mg/kg; ref. 23) or vehicle alone each Monday and second, either niclosamide (10 mg/kg) or vehicle alone each Monday (6 hours after the first injection; ref. 1). Wednesday, and Friday, for 4 to 8 weeks. All animals were kept in identical housing conditions and euthanized by cervical dislocation preceded by isoflurane inhalation. Animals received humane care in compliance with French Institutional Guidelines (INSERM and Université Paris Descartes – Ethics Committee CEEA 34).

Behavioral studies
Tactile sensitivity was evaluated using the von Frey test. The principle of this test is standardized: Once the mouse is calm and motionless, a hind paw is touched with the tip of a flexible fiber of given length and diameter. The fiber is pressed against the plantar surface at a right angle and exerts a vertical force. The force of application increases as long as the investigator is pushing the probe and until the fiber bends. This principle makes it possible for the investigator to apply a reproducible force to the skin surface. The scale of force used ranged from 0.008 to 0.400 g. The von Frey test was considered positive when the animal indicated a perception of the fiber by pulling back its paw (24). Paw movements associated with locomotion were not counted as a withdrawal response. Cold hyperalgesia was evaluated using the protocol described by Ta and colleagues (25). Mice were treated daily with oxaliplatin (3 mg/kg) or vehicle for 5 days, followed by 5 days of rest, for 2 cycles. Hyperalgesia was evaluated by the cold plate assay at the optimal temperature of 2°C ± 0.2°C as described previously (1, 25). The total number of brisk lifts of one or the other hind paw was counted as the response to cold hyperalgesia, and two observers were tasked with counting to ensure accuracy. Normal locomotion was distinct, involving coordinated movements of all four limbs that were excluded. A maximal cut-off time of 5 minutes was used to prevent tissue damage. A cold plate test was performed at baseline, during, and after drug treatment at the end of each of the two cycles over the 5-day period. Results are expressed as the mean ± SD of the observers’ counts.

Electrophysiologic exploration of oxaliplatin neurotoxicity
The sensory and motor excitation was assessed in vivo on mice under isoflurane anesthesia by minimally invasive electrophysiologic methods using the QTrac software written by Prof. H. Bostock (Institute of Neurology, London, United Kingdom), as described previously (26). Briefly, an anaesthetized mouse was placed on a heating pad to the maintain body temperature throughout the experiment (between 35.40 ± 0.04 and 35.47 ± 0.02°C, as determined in 29 mice using a rectal probe) to avoid nonspecific modifications of the measured excitability parameters. For sensory investigation, the compound nerve action potential (CNAP) was recorded using needle electrodes inserted into the base of mouse tail, in response to stimulation of the caudal nerve applied at the distal part of the tail, by means of surface electrodes. For motor investigation, electrical stimulation was delivered to the sciatic motor nerve, and the compound muscle action potential (CMAP) was recorded into the plantar muscle. The mouse was systematically submitted to the first session of excitability measurements (TRONDE protocol), allowing to determine the stimulus–response relationship (i.e., the CNAP or CMAP amplitude as a function of 1-ms stimulation intensity), and thus evaluate notably the CNAP or CMAP maximal amplitude, the stimulation intensity that had to be applied to
evoke a CNAP or CMAP of 50% maximal amplitude, and the latency measured from stimulation onset to peak amplitude, giving information on the global excitability state. For motor recordings, this first excitability test was followed by four different other ones performed together: (i) the strength–duration relationship (i.e., the intensity in relation to the duration of a stimulus necessary to evoke a given amplitude of CMAP), which evaluated the minimal intensity of infinitely long duration stimulation necessary to evoke a CMAP (rheobase) and the intensity duration of twice the rheobase stimulation necessary to evoke a CMAP (chronaxie), giving information on the axonal resting potential at the nodal membrane; (ii) the current–threshold relationship (i.e., the threshold changes at the end of 200-ms conditioning subthreshold depolarizing and hyperpolarizing currents ranging from 50% to 100% thresholds); (iii) the threshold electrotonus (i.e., the threshold changes during and after 100-ms conditioning subthreshold depolarizing and hyperpolarizing currents applied at ±40% thresholds), which evaluates the electrotonic changes in membrane potential, giving information on axonal accommodation capacities to depolarizations and hyperpolarizations; and (iv) the recovery cycle (i.e., the excitability changes that occur following a CMAP), which evaluated the refractory periods (during which membrane excitability is either nil or markedly decreased) followed by the suprathreshold and late subnormal periods (during which membrane excitability is increased and decreased, respectively). As a whole, more than 30 parameters could be determined from these excitability tests and analyzed. It is worth noting that each specific excitability test provides additional and complementary information regarding, on one hand, the functional status of ion channels and electrogenic pumps and, on the other hand, membrane properties (27, 28).

**Confocal microscopy**

The experiments were carried out on single myelinated axons isolated from the sciatic nerves, as detailed previously (29). Briefly, sciatic nerve sections of about 2 cm in length were removed from their sheaths, dissected, and fixed for 1 hour in PBS (1 ×) with 2% PFA, then rinsed three times with PBS (1 ×). Sciatic nerves were deposited on microscope slides, myelinated axons were gently teased apart from the main trunk, and preparations were kept at –20°C until use. Just before the experiments, sciatic nerves were rehydrated for about 1 hour with a standard physiologic solution containing 154 mmol/L NaCl, 5 mmol/L KCl, 2 mmol/L CaCl₂, 1 mmol/L MgCl₂, 11 mmol/L glucose, and 5 mmol/L HEPES, buffered at pH 7.4 with NaOH. Preparations were then exposed for 30 minutes to the fluorescent dye FM1-43 (Molecular Probes) dissolved in a standard physiologic solution to stain the plasma membranes of the myelinated axons and washed with dye-free solution before imaging. A Zeiss LSM 510 META (Carl Zeiss) multiphoton scanning confocal microscope, mounted on an upright microscope and controlled with the manufacturer’s software and workstation, was used for optical sectioning of myelinated axons and subsequent 3D high-resolution digital reconstruction of their structure. Images were collected using a 63× oil immersion objective with a 1.40 numerical aperture (Zeiss Plan-Apochromat), following excitation of FM1-43 with the 488-nm wavelength line of an Argon ion laser, and then digitized at 12-bit resolution into a 512 × 512 pixel array. Images were then analyzed using ImageJ software (NIH, Bethesda, MD). Quantification of morphometric parameters of myelinated axons was performed by measuring the intermodal diameter, nodal diameter (D) and nodal length (L). Assuming the simplest geometry in which a node of Ranvier approaches a cylinder, the nodal volume (V) was then determined as $V = \pi (D/2)^2$.  

**IHC and histology**

Intraepidermal nerve fibers density and myelin sheath of sciatic nerves were evaluated by IHC and histology. Luxol Blue Fast allows for fast, reliable, and reproducible staining of myelin in transversal section of sciatic nerves (30–32). Briefly, sciatic nerves were removed and preserved in formalin before being fixed in paraffin and stained with coloring solution (Luxol Blue Fast Solution). Sections of skin from the hind paws of mice were immersed in buffered 4% formalin (VWR Chemicals, Labonord SAS) and immersed in successive baths of increasing concentration of ethanol (50%, 70%, 90%, and 100%). Samples were then immersed in xylene substitute before being fixed in paraffin, kept at 4°C, and cut into 6-μm thick slices. Samples were then dewaxed in three successive baths of xylene substitute for 3 minutes and rehydrated in ethanol baths for 1 minute each, starting with two baths of pure ethanol followed with baths of 90%, 70%, and 30% ethanol and two baths of H₂O. Slides were then washed in PBS for 2 minutes before being immersed in citrate buffer at 95°C for 10 minutes. Samples were then washed in three baths of PBS of 5 minutes each. Samples were then permeabilized [PBS, Triton X-100 (0.25%)] for 10 minutes before being rinsed in PBS in three baths of 5 minutes each and immersed in a blocking solution (PBST, 10% goat serum, 1% BSA) for at least 180 minutes. Samples were then incubated at 4°C overnight in the primary antibody (Abcam, ab10404, rabbit polyclonal to PGP9.5, 1:1,000) before being rinsed in PBS in three baths of 5 minutes each and incubated in the secondary antibody (Sigma, P9887, anti-rabbit IgG FITC-conjugate, 1:1,000) at room temperature in the dark. Prior to mounting (Thermo Scientific, Shandon Immun-Mount), slides were washed with PBS in three baths of 5 minutes each. Images were collected using a Nikon Eclipse 80i microscope with a Nikon Plan Fluor 100×/1.30 oil immersion DIC H/N2 objective.

**Tumor growth**

A total of 1 × 10⁶ viable CT26 cells, as determined by Trypan blue staining and resuspended in DMEM, were then injected subcutaneously into the back of BALB/cRj mice. When tumors reached a mean size of 200 to 500 mm³, animals were randomized and received a single weekly injection of either oxaliplatin (10 mg/kg) or vehicle. At the same time, mice were injected or not with niclosamide (10 mg/kg) every day. Following randomization, tumor size was measured with a numeric caliper twice a week for 3 weeks. To comply with ethical guidelines, tumor growth experiments were stopped 3 weeks after the first oxaliplatin injection. Tumor volume was calculated as follows: $V = (L × W^2)/2$, where $L$ is the longest and $W$ the shortest radius of the tumor in millimeters. Results are expressed as means ± SD of tumor volumes ($n = 8$ in each group).

**ELISA assays**

Sera were retro-orbitally punctured 4 weeks after the first injection of oxaliplatin. Samples were diluted (1:4) in assay diluent 1× or ELISA/ELISPOT diluent 1× (the manufacturer’s kits respective diluent solutions) before being distributed on
ELISA 96-well plates specific of IL6 and TNFα (Mouse IL-6 ELISA Ready-SET-Go! and Mouse TNF ELISA Ready-SET-Go!, eBioscience). Concentrations were calculated from a standard curve according to the manufacturer's protocol.

Advanced oxidized protein products assay
The level of oxidative stress was determined in all experimental mice groups as described previously (1). Prior to being dispensed into a 96-well plate (Corning), sera were diluted (1:4) in PBS. Acetic acid was then added to each well (20 μL). A standard curve was drawn after adding 10 μL 1.16 mol/L potassium iodide to 100 μL chlorammine-T solution (0–100 μmol/L, Sigma-Aldrich) and 20 μL acetic acid. The blank was prepared similarly, but the chlorammine-T solution was replaced by an equal volume of PBS. The absorbance was read immediately at 340 nm. The advanced oxidation protein products (AOPP) concentrations were expressed as micromoles per liter of chloramines-T equivalents (1).

Statistical analysis
Statistical analysis was performed using GraphPad Prism 5. Artwork was also created using GraphPad Prism 5, except for electrophysiologic study artwork, which was created using the Qtrac software. Differences between values were tested using the two-tailed Student t test, two-way ANOVA, or the nonparametric Mann–Whitney U test, depending on the equality of variances estimated using Lilliefors test. They were considered significant when \( P < 0.05 \). P values are denoted as follows: \(^*\); \( P < 0.05 \); \(^*\); \( P < 0.01 \); \(^*\); \( P < 0.001 \); \(^*\); \( P < 0.0001 \); NS, not significant.

Results
To assess the neuroprotective potential of niclosamide on oxaliplatin-induced peripheral neuropathies, we used a cellular model of the condition involving the exposition of neuron-like cells to both the chemotherapy and the teniacide. To further evaluate the therapeutic value of niclosamide, the efficacy of oxaliplatin when associated with the teniacide also had to be investigated, as niclosamide could have dampened the antitumor effect of the chemotherapy. Our results indicate that niclosamide modulated cell viability in a cell type–dependent manner. Niclosamide permitted a greater cytotoxicity of oxaliplatin on C126 and THP1 cells (Fig. 1A and C). Inversely, in niclosamide-treated neuron-like N2a cells, the cytotoxicity of oxaliplatin was diminished (Fig. 1B). Niclosamide did not further increase oxaliplatin-mediated cell death of HUVECs (Fig. 1C). This cell type–dependent death was accompanied by a greater rise in \( H_2O_2 \) production (Fig. 1A and D), while protection of neuron-like cells was mediated by niclosamide through a significant decrease in \( H_2O_2 \) production (Fig. 1B). The innocuity of niclosamide on HUVECs that are analogous to the cells forming vasa nervorum in vivo is of prime importance as an in vitro deleterious effect of the teniacide might have reflected an in vivo reduction in blood flow supply to the peripheral nerves possibly leading to peripheral neuropathies. Cell type–dependent \( H_2O_2 \)-mediated cell death was explained through differential basal levels of GSH (Fig. 1E). Indeed, N2a cells produce higher levels of GSH than C126 under normal conditions, therefore allowing for greater cytotoxicity of niclosamide on the latter cell line when also incubated with oxaliplatin (Fig. 1A and B).

The aforementioned in vitro results suggested that, in vivo, niclosamide could potentially prevent neurologic alterations resulting from oxaliplatin infusions while potentiating their efficacy. To determine whether niclosamide could indeed abrogate the main limiting factor of oxaliplatin treatment, mice were subjected to neurologic tests similar to those used in patients treated by oxaliplatin. A von Frey test after 4 weeks of treatment showed that the withdrawal threshold was four times higher in mice treated with oxaliplatin than in mice treated with vehicle alone (Fig. 2A). Niclosamide corrected this hypotesthesia and permitted the maintenance of tactile sensitivity in mice also treated with oxaliplatin (Fig. 2A).

In addition to diminished tactile sensitivity, patients treated by oxaliplatin also suffer from altered thermal perception at their extremities, and mice models have been developed to mimic these neurologic disorders (5). After oxaliplatin cycle 1, the mean number of brisk lifts was four times higher in oxaliplatin mice than in mice injected with vehicle alone (Fig. 2B). The same changes were observed after the second cycle of treatment. Association with niclosamide rescued this hyperalgia (Fig. 2B). Together, these data demonstrate in vivo a beneficial effect of niclosamide on key peripheral functions.

Oxaliplatin-treated mice presented significant alterations, consistent with membrane hyperexcitability, in excitability waveforms and derived parameters, compared with animals injected with vehicle alone. For sensory recordings (Fig. 3), these alterations consisted in (i) a decreased CNAP amplitude; (ii) a consequent enhanced latency, that is, a decreased nerve conduction velocity, suggesting apparent reduction in the number of fast-conducting fibers or decrease in density and/or functioning of nerve transitory sodium channels; and (iii) a reduced stimulus intensity to evoke 50% of maximal CNAP amplitude, indicating modification in the voltage dependence of these channels. For motor recordings (Supplementary Fig. S1; Supplementary Table S1), the alterations involved mainly (i) an enhanced CNAP amplitude and a reduced stimulus intensity to evoke 50% of maximal CMAP amplitude, suggesting apparent decreased density and/or functioning of fast potassium channels and modification in the voltage dependence of transitory sodium channels, respectively, with no change in the latency, that is, no modification in the neurotransmission velocity; (ii) reduced minimum and hyperpolarizing slopes of the current–threshold relationship, indicating decreased density and/or functioning of cyclic nucleotide-gated channels; (iii) increased threshold changes in response to hyperpolarizing currents (threshold electrotonus), likely caused by reduced inward rectifier potassium channels; and (iv) increased refractoriness and lower superexcitability (recovery cycle), reflecting again transitory sodium and fast potassium channel dysfunctioning, respectively. The absence of oxaliplatin-induced modification of strength–duration relationship (Supplementary Fig. S1) and threshold changes in response to depolarizing currents (Supplementary Fig. S1), and derived parameters (Supplementary Table S1), strongly suggests that the antitumor agent does not affect the density and/or functioning of persistent sodium channels and slow potassium channels, respectively, and thus does not produce any change in resting membrane potential. This latter conclusion is supported by the absence of oxaliplatin effect on parameters #24 (Supplementary Table S1; threshold electrotonus) and #14 (Supplementary Table S1; recovery cycle).
Figure 1.
In vitro effects of oxaliplatin associated or not with niclosamide on viability and oxaliplatin-induced ROS production. A, CT26 cells. B, N2a cells. C, HUVEC. D, THP1 cells. Viability was expressed as percent ± SD versus cells in culture medium alone (100% viability). E, Reduced GSH was also assessed under normal cell culture growth conditions with monochlorobimane. Data from at least three independent experiments have been pooled and were expressed as means ± SD of triplicates.

*P < 0.05; **P < 0.01 versus oxaliplatin.
The oxaliplatin-induced sensory and motor alterations were not detected in mice injected with oxaliplatin plus niclosamide or niclosamide alone (Fig. 3; Supplementary Fig. S1; Supplementary Table S1). These observations further validate niclosamide as a potentially neuroprotective molecule, as they highlighted the maintenance of the peripheral nervous system functioning by the teniaceid.

The morphology of myelinated axons of mouse sciatic nerves was examined using confocal microscopy (Fig. 4). Quantification of morphometric parameters of single myelinated axons revealed a significant increase in the nodal diameter, length, and volume, as functions of the internodal diameter, in mice injected for 5 weeks with oxaliplatin, compared with vehicle-treated animals (Fig. 4B, left; Supplementary Table S2). These results are likely the consequence of oxaliplatin-induced membrane hyperexcitability. In these animals, a reduction in the internodal diameter was also observed, which may reflect either a preferential loss of large myelinated nerve fibers or an alteration in myelin sheath layers surrounding the axons. These morphometric parameters were not altered in mice injected for 5 weeks with oxaliplatin plus niclosamide (Fig. 4B, middle; Supplementary Table S2) or niclosamide alone (Fig. 4B, right; Supplementary Table S2). Therefore, oxaliplatin induced a mixed form of peripheral neuropathy, with both the myelin sheath being thinner and the axons being swollen as indicated by the increase in the nodal diameter. Niclosamide addressed both of these parameters, which may account for its efficacy in maintaining nervous functioning of the peripheral nervous system in oxaliplatin-treated mice.

The density of intraepidermal nerve fibers was examined in the paws of mice injected with vehicle, oxaliplatin, oxaliplatin plus niclosamide, or niclosamide alone for 8 weeks. Staining of the nerve fibers with PGP9.5 antibody revealed a reduced intraepidermal nerve fiber density in the paw skin of oxaliplatin mice (Fig. 5A). Niclosamide abrogated this alteration in oxaliplatin mice and maintained density of PGP9.5-stained nerves in mice that had also been treated with oxaliplatin (Fig. 5B).
The myelin content of sciatic nerves from experimental and control groups of mice was also assessed. Analyses of myelin content revealed a demyelination in oxaliplatin-treated mice compared with animals injected with vehicle, oxaliplatin plus niclosamide, or niclosamide alone (Fig. 5C). Staining of the nerves with Luxol allowed the quantification of the demyelination in sciatic nerves from oxaliplatin mice (Fig. 5D). Niclosamide abrogated the reduction in myelin sheath thickness observed in oxaliplatin mice, which translated in either partial or total degradation of the myelin sheath surrounding the axons of neuropathic mice and higher G-ratios (Fig. 5D).

Results obtained from the neurologic tests provided a rationale for the use of niclosamide as a neuroprotective drug, but further data regarding its effect on oxaliplatin efficacy had to be gathered to guarantee its safety in addressing the primary aspect of the condition, which is tumor growth. From the 11th day of treatment on, mice treated with niclosamide alone had smaller tumors than nontreated mice (2,083 ± 229.1 mm³ with niclosamide vs. 2,819 ± 173.0 mm³ with vehicle). Niclosamide maintained oxaliplatin efficacy, as mice treated from day 4 on with oxaliplatin plus niclosamide had, from day 4, smaller tumors than mice treated with vehicle (at day 4, 253.5 ± 30.01 mm³ with oxaliplatin plus niclosamide vs. 782.0 ± 98.54 mm³ with vehicle, and at day 21, 1,167 ± 182.9 mm³ with oxaliplatin plus niclosamide vs. 9,001 ± 448.8 mm³ with vehicle; Fig. 6A). Oxaliplatin plus niclosamide-treated mice had similar tumor sizes than oxaliplatin-treated mice at 3 weeks (1,167 ± 182.9 mm³ with oxaliplatin plus niclosamide vs. 1,127 ± 186.0 mm³ with oxaliplatin alone; Fig. 6A).

To evaluate the systemic effects of niclosamide on proinflammatory cytokine levels, serum samples were analyzed. Serum IL6 levels were significantly increased in the oxaliplatin group of mice compared with the oxaliplatin plus niclosamide, vehicle, and niclosamide groups (4,812 ± 1,299 ng/mL with oxaliplatin vs. 1,064 ± 0.943 ng/mL with oxaliplatin plus niclosamide, vs. vehicle 1,477 ± 0.451 ng/mL, and vs. niclosamide 1,631 ± 0.647 ng/mL; Fig. 6B). Serum TNFα levels were also significantly increased in the oxaliplatin group compared with all other groups of mice (0.9076 ± 0.3155 pg/mL with oxaliplatin vs. 0.1273 ± 0.1127 pg/mL with oxaliplatin plus niclosamide, vs. vehicle 0.1436 ± 0.0553 pg/mL, and vs. niclosamide 0.0822 ± 0.0689 pg/mL; Fig. 6C). Serum AOPPs were also found to be significantly increased in mice receiving only oxaliplatin compared with the other experimental mice groups (0.0104 ± 0.01885 μmol/L with oxaliplatin vs. 0.05587 ± 0.006318 μmol/L with oxaliplatin plus niclosamide, vs. vehicle 0.05180 ± 0.006064 μmol/L, and vs. niclosamide 0.05057 ± 0.008539 μmol/L; Fig. 6D).

Discussion

This report evidences the beneficial effects of niclosamide on oxaliplatin-induced peripheral neuropathies, muscle cramps, and tumor growth. Niclosamide protects neuron-like cells while potentiating the cytotoxic effects of the chemotherapy on cancer cells. Thus, in vivo, this molecule prevents oxaliplatin-induced peripheral neuropathies without impairing chemotherapy efficacy. To test our hypothesis that niclosamide is effective in preventing both forms of peripheral neuropathy induced by oxaliplatin, we used a murine model described previously (1).
Our results show that neuron-like cells retain their integrity when exposed to oxaliplatin if associated with niclosamide. These cells produce reduced levels of H$_2$O$_2$ compared with cells exposed to oxaliplatin alone. Furthermore, niclosamide also potentiates the cytotoxic effect of oxaliplatin on tumor cells via an increase in H$_2$O$_2$ production. These findings are of prime interest as ROS are key mediators of oxaliplatin-induced neuron cytotoxicity (26). In addition, tumor growth can also be regulated by modulating the production of ROS (10). The differences in ROS production between cell types exposed to niclosamide could be related to basal levels of GSH (33). Interestingly, we and others have shown that normal cells and tumor cells respond differently to ROS-induced cell death due to differences in basal H$_2$O$_2$ levels and antioxidant defense systems between cell types (10, 34, 35). Tumor cells are more sensitive to ROS-induced cell death than normal cells due to increased metabolism of tumor cells and antioxidant defense exhaustion. Interestingly, in normal cells, similar levels that kill tumor cells favor cellular viability and proliferation through adaptation and mobilization of antioxidant defenses, usually through NRF2 induction (36, 37). Furthermore, GSH homeostasis is of prime importance for neurons as their depletion in this antioxidant molecule ultimately leads to their senescence mediated by oxidative stress (38). Several studies concur with the observation that GSH-mediated detoxification of H$_2$O$_2$ is paramount to address neurologic disorders, may they be central or peripheral (39, 40). In clinical settings, GSH infusions significantly reduced the severity of the neurodegenerative side effects of oxaliplatin (41). These results prompted us to investigate in vivo the effects of niclosamide on oxaliplatin-treated mice.

A diminished nociception was observed in vivo in oxaliplatin mice. This impairment was abrogated by associating niclosamide to the chemotherapy. This finding can be linked with data gained from immunohistochemical studies that revealed reduced intraepidermal nerve fiber density in mice treated with...
oxaliplatin (42, 43). Niclosamide permits the maintenance of the density of these fibers in oxaliplatin mice. It is possible that niclosamide protects these fibers by limiting local inflammation mediated by the activation of Langerhans cells and astrocytes (44) and oxidative species. ROS production and inflammation has been linked to the etiology of peripheral neuropathies (45). ROS may not only act locally but also favor a state of sensitization to pain through spinal mechanisms, namely at the dorsal horn region, resulting in centrally lowered pain thresholds (46). These findings were further explained through the use of ROS scavenger molecules, which reduced the development of both thermoalgesia but also mechanically triggered pain in a murine model of neuropathic pain (47). Cold hyperalgesia induced by oxaliplatin treatment is abrogated by niclosamide. Thermoception is achieved through two different types of nerve fibers: A delta-type nerve fibers and C-type nerve fibers. Unlike C nerve fibers, A delta nerve fibers are myelinated and convey action potentials of high speed. Niclosamide could act on morphologic properties of myelinated fibers while maintaining functional properties of larger fibers conveying slower action potentials.

Electrophysiologic sensory and motor recordings from the mouse, in vivo, reveal oxaliplatin-induced functional impairment that consists in a global membrane hyperexcitability state, including, in particular, reduced stimulus intensity to evoke 50% of maximal CNAP or CMAP amplitude, and lower axonal accommodation capacities to hyperpolarizations, without any change in resting membrane potential. This functional impairment translates apparent reduction in the number of fast-conducting sensory fibers and modifications in the density and/or functioning of transitory sodium channels, inward rectifier, and fast potassium channels, as well as cyclic nucleotide-gated channels, those of

---

**Figure 5.** Characterization of Cutaneous Nerve Fiber Density by PGP9.5 Staining and Paraffin-Included Luxol® Blue Fast (Myelin)-Treated Transversal 8 μm Sections of Sciatic Nerves From Mice. A, Staining with PGP9.5 of cutaneous nerve fibers. B, Analysis of intraepidermal nerve fiber density from paw skin samples (6 μm) mice treated for 8 weeks with vehicle, oxaliplatin, oxaliplatin plus niclosamide or niclosamide as determined by a masked pathologist using a two-tailed Student’s t test. ***, P < 0.001** versus oxaliplatin. Error bars represent standard deviation of the mean. Magnification ×40. Scale bars, 100 μm. C, Histological staining of peripheral myelin with Luxol® Blue Fast. D, Analysis of myelin content as determined by a masked pathologist using a two-tailed Student’s t test. ***, P < 0.001** versus oxaliplatin. E, Compiled analysis of myelin content. Error bars represent standard deviation of the mean. A two-tailed Student’s t test was performed. ***, P < 0.001** versus oxaliplatin. Magnification ×100. Scale bars, 2 μm.
Niclosamide Increases the Therapeutic Index of Oxaliplatin

Figure 6.
Evaluation of oxaliplatin efficacy in combination with niclosamide in a tumor growth model. A, Tumor size in mice injected subcutaneously into the back with $10^6$ CT26 cells and treated with vehicle, oxaliplatin, oxaliplatin associated with niclosamide, or niclosamide alone. B, Mean values ± SD of tumor volumes under each condition. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ versus vehicle. ELISA-quantified levels of IL6 in sera from mice treated for 4 weeks with vehicle, oxaliplatin, oxaliplatin associated with niclosamide, or niclosamide alone. C, Data, means ± SD. *, $P < 0.05$, versus vehicle or oxaliplatin. ELISA-quantified levels of TNFα in sera from mice treated for 4 weeks with vehicle, oxaliplatin, oxaliplatin associated with niclosamide, or niclosamide alone. D, AOPPs levels in sera from mice treated for 4 weeks with vehicle, oxaliplatin, oxaliplatin associated with niclosamide, or niclosamide alone. Not significant. E, ELISA-quantified levels of IL6 in sera from mice treated for 4 weeks with vehicle, oxaliplatin, oxaliplatin associated with niclosamide, or niclosamide alone. F, AOPPs levels in sera from mice treated for 4 weeks with vehicle, oxaliplatin, oxaliplatin associated with niclosamide, or niclosamide alone. Not significant. G, ELISA-quantified levels of TNFα in sera from mice treated for 4 weeks with vehicle, oxaliplatin, oxaliplatin associated with niclosamide, or niclosamide alone. H, AOPPs levels in sera from mice treated for 4 weeks with vehicle, oxaliplatin, oxaliplatin associated with niclosamide, or niclosamide alone. Not significant.
of oxaliplatin in vivo is most likely linked to oxaliplatin’s inherent antitumor activity being at this dosage (10 mg/kg) sufficient to cause tumor cell death.

Further investigations focusing on potential neuroprotection by niclosamide could shed light on the benefit that patients could gain from receiving this well-tolerated teniociate in association with other treatments currently available to address axonal, demyelinating, or mixed peripheral neuropathies of various etiologies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: O. Cerles, R. Coriat, F. Batteux, C. Nico Development of methodology: O. Cerles, M.-A. Guillaumot, R. Coriat, N. Kavian, F. Batteux, C. Nico Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): O. Cerles, E. Benoit, C. Chéreau, S. Chouzenoux, M.-A. Guillaumot, R. Coriat, T. Lenoir, I. Marcellin, C. Nico Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): O. Cerles, E. Benoit, C. Chéreau, S. Chouzenoux, M.-A. Guillaumot, R. Coriat, N.E.B. Saidu, F. Batteux, C. Nico

References


